wounds) in dogs caused by susceptible strains of *Staphylococcus intermedius* and *Streptococcus canis* (Group G).

(2) **Cats**—(i) **Amount.** Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.

(ii) **Indications for use.** For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *Pasteurella multocida*.

[73 FR 29685, May 22, 2008]

§ 522.313 Ceftiofur injectable dosage forms.

§ 522.313a Ceftiofur crystalline free acid.

(a) **Specifications.** The product is a suspension of ceftiofur crystalline free acid.

(1) Each milliliter (mL) contains 100 milligrams (mg) ceftiofur equivalents.

(2) Each mL contains 200 mg ceftiofur equivalents.

(b) **Sponsor.** See No. 000009 in § 510.600(c) of this chapter.

(c) **Related tolerances.** See § 556.113 of this chapter.

(d) **Special considerations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e) **Conditions of use**—(1) **Swine.** The formulation described in paragraph (a)(1) of this section is used as follows:

(i) **Amount.** 5.0 mg CE per kilogram (kg) of body weight by intramuscular injection in the postauricular region of the neck.

(ii) **Indications for use.** For the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, and *Streptococcus suis*. For the control of SRD associated with *A. pleuropneumoniae*, *P. multocida*, *H. parasuis*, and *S. suis* in groups of pigs where SRD has been diagnosed.

(iii) **Limitations.** Following label use as a single treatment, a 14-day pre-slaughter withdrawal period is required. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal.

(2) **Cattle.** The formulation described in paragraph (a)(2) of this section is used as follows:

(i) **Amount.** 6.6 mg ceftiofur equivalents per kg of body weight as a single injection. For subcutaneous injection in the middle third of the posterior aspect of the ear where it attaches to the head (base of the ear) in beef and non-lactating dairy cattle. For subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) in lactating dairy cattle.

(ii) **Indications for use.** For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni* in beef, non-lactating dairy, and lactating dairy cattle. For the control of respiratory disease in beef and non-lactating dairy cattle which are at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, and *H. somni*. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with *Fusobacterium necrophorum* and *Porphyromonas levii* in beef, non-lactating dairy, and lactating dairy cattle.

(iii) **Limitations.** Following label use as a single treatment, a 13-day pre-slaughter withdrawal period is required. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal.

(3) **Horses.** The formulation described in paragraph (a)(2) of this section is used as follows:

(i) **Amount.** Two intramuscular injections, 4 days apart, at a dose of 3.0 mg/lb (6.6 mg/kg) body weight.

(ii) **Indications for use.** For the treatment of lower respiratory tract infections in horses caused by susceptible strains of *Streptococcus equi* ssp. *zooepidemicus*.

(iii) **Limitations.** Do not use in horses intended for human consumption.


§ 522.313b Ceftiofur hydrochloride.

(a) **Specifications.** Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) ceftiofur equivalents.

(b) **Sponsor.** See No. 000009 in § 510.600(c) of this chapter.

(c) **Related tolerances.** See § 556.113 of this chapter.